Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis/Amgen End CNP520 Studies, Leaving Eisai/Biogen With Last BACE Inhibitor In The Clinic

Executive Summary

An interim look at two Phase II/III trials showed the drug worsened cognition in people at high risk of developing Alzheimer's disease. This is the 16th failure of a BACE-targeting therapy.

Advertisement

Related Content

Biogen Growth Continues, But Analysts Worry About Near-Term R&D Prospects
No More Deal? Novartis, Amgen Trade Lawsuits Over Aimovig Agreements
After Abeta Blow, Biogen And Eisai Get BACE Boost
Why Biogen/Eisai's Aducanumab Failure Is Not The End Of Amyloid Hypothesis
Lilly/AstraZeneca's Lanabecestat Becomes Latest BACE Inhibitor Casualty
More Alzheimer's Pain As J&J Pulls Plug On BACE Inhibitor
M&A Pressure Mounts For Merck & Co After Alzheimer's Drug Dismissed
Deal Watch: Novartis Signs Deals In Migraine & Diabetes
Amgen, Novartis Trade Rights For Migraine, Alzheimer's Drugs

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC125530

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel